Share on facebook Share on Twitter Share on Google Plus Share This

Heart Failure

Heart failure happens when the heart cannot pump enough blood for the body.

Programs + Services


Clinical Nutrition

The Division of Clinical Nutrition at Tufts Medical Center provides inpatient and outpatient nutritional services.
More information about programs and services


Heart Failure + Cardiac Transplant Center

Tufts Medical Center's Heart Failure and Cardiac Transplant Center is a leader when it comes to heart transplantation. Learn more about the care provided.
More information about programs and services


Women's Heart Center

Discover The Women’s Heart Clinic at Tufts Medical Center and learn more about the cardiologists dedicated to providing women with the best heart care.
More information about programs and services

Doctors + Care Team

Marvin A. Konstam, MD

Marvin A. Konstam, MD

Title(s): Chief Physician Executive, The CardioVascular Center; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-6293
Fax #: 617-636-7667

Heart failure, cardiac transplant

View Full Profile

James E. Udelson, MD

James E. Udelson, MD

Title(s): Chief, Division of Cardiology; Director, Nuclear Cardiology Laboratory; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8066
Fax #: 617-636-7175

Cardiac imaging, heart failure

View Full Profile

Alan T. Kono, MD

Alan T. Kono, MD

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure

View Full Profile

Amanda Vest, MBBS, MPH

Amanda Vest, MBBS, MPH

Title(s): Medical Director, Cardiac Transplantation Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Cardiology, heart failure, heart transplantation, mechanical circulatory support

View Full Profile

Ayan R. Patel, MD

Ayan R. Patel, MD

Title(s): Director, Cardiovascular Imaging and Hemodynamic Laboratory; Director, Women's Heart Center; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-2273
Fax #: 617-636-8070

Echocardiography, heart failure, women's heart disease

View Full Profile

Daniel Levine, MD

Daniel Levine, MD

Title(s): Cardiologist
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure, coronary artery disease

View Full Profile

David DeNofrio, MD

David DeNofrio, MD

Title(s): Director, Advanced Heart Failure Program; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure, cardiac transplantation

View Full Profile

David M. Venesy, MD

David M. Venesy, MD

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-7175

Heart failure

View Full Profile

Frederick  Y. Chen, MD, PhD

Frederick Y. Chen, MD, PhD

Title(s): Chief, Cardiac Surgery; Professor of Surgery, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical treatment of acquired heart disease, surgical repair of valvular heart disease, minimally invasive surgery, arrhythmia surgery, heart transplantation, circulatory assist devices, hypertrophic cardiomyopathy (HCM)

View Full Profile

Hassan Rastegar, MD

Hassan Rastegar, MD

Title(s): Senior Cardiothoracic Surgeon; Professor, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical treatment of acquired heart disease, surgical repair of valvular heart disease, surgical repair of hypertrophic cardiomyopathy, minimally invasive surgery, arrhythmia surgery, heart transplantation, circulatory assist devices

View Full Profile

Kenneth G. Warner, MD

Kenneth G. Warner, MD

Title(s): Senior Cardiothoracic Surgeon; Program Director for the Thoracic Surgery Residency; Associate Professor, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical management of adult and pediatric heart disease, heart transplantation

View Full Profile

Masashi Kawabori, MD

Masashi Kawabori, MD

Title(s): Cardiothoracic Surgeon; Assistant Professor, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery, Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Heart transplantation, mechanic circulatory support, adult general cardiac surgery

View Full Profile

Michael S. Kiernan, MD, MSc

Michael S. Kiernan, MD, MSc

Title(s): Director, Ventricular Assist Device Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure, cardiac transplantation, ventricular assist devices

View Full Profile

Navin K. Kapur, MD, FAHA, FACC, FSCAI

Navin K. Kapur, MD, FAHA, FACC, FSCAI

Title(s): Executive Director, The CardioVascular Center for Research and Innovation (CVCRI); Director, Acute Mechanical Circulatory Support Program; Director, Interventional Research Laboratories; Director of Cardiac Biology Research Center, Molecular Cardiology Research Institute (MCRI); Associate Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8252
Fax #: 617-636-5913

Interventional cardiology, advanced heart failure, mechanical circulatory support

View Full Profile

Nicole M Orr, MD, FACC

Nicole M Orr, MD, FACC

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 781-762-0009
Fax #: 781-255-8880

Geriatric cardiology, echocardiography

View Full Profile

Robb Kociol, MD

Robb Kociol, MD

Title(s): Cardiologist
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Advanced heart failure, cardiac transplant, mechanical circulation support

View Full Profile

Research + Clinical Trials


A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
More information about research and clinical trials


Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial  (TAVR UNLOAD)

The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.

Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis


More information about research and clinical trials


Entrestotm (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

The purpose of this study is to test whether EntrestoTM, a newly approved drug for heart failure that combines sacubitril and valsartan, improves symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. EntrestoTM has been studied in only a very small number of patients with advanced heart failure, like you. This study is beind done to obtain more information on the benefits and risks of EntrestoTM in patients with advanced heart failure. Both EntrestoTM and valsartan have previously been approved by the U.S. Food and Drug Administration (FDA)for people with heart failurea nd are available by prescription from a licensed medical doctor. Currently EntrestoTM is only available under the brand name EntrestoTM, there is no generic form of EntrestoTM. You do not have to take part in this study in order to receive EntrestoTM.
More information about research and clinical trials


Non-Invasive Measurement of Capillary Oxygenation during Exercise in Ambulatory Advanced Heart Failure Patients

At Tufts Medical Center, we are continually evaluating different approaches to monitor and improve the care of our patients with advanced systolic heart failure. We are currently partnering with a company that has developed a non-invasive probe that measures capillary oxygenation through the skin. The probe attaches to the skin with a temporary adhesive and records the amount of oxygen in the blood cells passing through the skin. This technology may help us to detect when patients with abnormal heart pumping function (heart failure) are not circulating enough blood to their body. We have designed a study using this non-invasive probe to measure capillary oxygenation during exercise stress tests in patients with systolic heart failure and without systolic heart failure. Both groups of patients will have already been scheduled to undergo a treadmill exercise tests for standard clinical indications at Tufts Medical Center. We attach the adhesive probe to the skin on the base of the thumb and on the forearm during the exercise test. Study participation ends at the conclusion of the stress test, and the adhesive probe is removed. We hope to identify the differences between blood supply to the skin during exercise in patients with normal heart function versus those with systolic heart failure.
More information about research and clinical trials


A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

This is a prospective, multicenter, phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure (HF) with preserved Ejection Fraction (HFpEF). The objective of this event-driven trial is to demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF > 40%) under stable treatment of HF symptoms. Empagliflozin is an orally available, potent, and selective inhibitor of the renal SGLT-2. Its selective inhibition reduces renal reabsorption of sodium and glucose. This leads to both increased urinary sodium and glucose excretion. While the urinary sodium excretion returns to normal within few days of empagliflozin administration, the effect on urinary glucose continues. The study treatment period will run for approximately 20- 38 months, until the required number of adjudicated primary events are reached. In Addition to the treatment period there is a 4-21 day screening period and a 30 day follow up visit.
More information about research and clinical trials


A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

This is a prospective, multicenter, phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure (HF) with reduced Ejection Fraction (HFrEF). The objective of this event-driven trial is to demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF ≤40%) under stable treatment of HF symptoms. Empagliflozin is an orally available, potent, and selective inhibitor of the renal SGLT-2. Its selective inhibition reduces renal reabsorption of sodium and glucose. This leads to both increased urinary sodium and glucose excretion. While the urinary sodium excretion returns to normal within few days of empagliflozin administration, the effect on urinary glucose continues. The study treatment period will run for approximately 20- 38 months, until the required number of adjudicated primary events are reached. In Addition to the treatment period there is a 4-21 day screening period and a 30 day follow up visit.
More information about research and clinical trials


Prospective Hemodynamic Assessment of Cardica Resynchronization Therapy Effectiveness Following Left Ventricular Assist Device Support

To understated the effects of different pacemaker settings on heart function in patients with LVADS.
More information about research and clinical trials


A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure

This is a research study to investigate the effectiveness and safety of a device for patients with heart failure with preserved ejection fraction (HFpEF). Patients with a left ventricular ejection fraction greater than or equal to 40%, symptoms of heart failure and elevated filling pressures on a test called a right heart catheterization may be eligible to enroll. Participation in this multicenter study involves being randomly assigned either to implantation of an Inter Atrial Shunt Device (IASD) System II, or a sham procedure. Participants will be followed by the Tufts Heart Failure Research Team at regular intervals, for a total of 5 years; however they will remain under the care of their usual Cardiologist. The IASD System II consists of a self-expanding metal structure that is placed into the wall between the upper chambers of the heart (right and left atria) to enable blood to move between these chambers. For HFpEF patients with high pressures in the left atrium, it is thought that enabling blood to move from the left atrium into the right atrium could improve symptoms such as shortness of breath. This device is not yet approved in the United States. Please look at the study website for more information (www.treatmyheartfailure.com).
More information about research and clinical trials


Subcutaneous Furosemide in Acute Decompensated Heart Failure

The purpose of this study is to test if sending you home early from the hospital with a furosemide pump will improve your outcome after a heart failure admission. An investigational pump and drug combination - the sc2WearPump and Furosemide Injection Solution (SCP-101, made scPharmaceuticals), will be used to provide you with the drug you need and the study will also determine if this combination product is safe. "Investigational" means that the combination pump/drug is currently being tested in research studies and is not approved by the US Food and Drug Administration (FDA) for standard medical use. Furosemide is already approved by the FDA for the treatment of heart failure, but tihs study will test a furosemide injection given under the skin using a pump (sc2Wear Pump) applied to the belly.
More information about research and clinical trials


Accuracy of echocardiographic estimation of atrial pressure: A prospective, observational study

The purpose of this study is to determine how accurate transthoracic echocardiogram (echo) is at estimating the pressures within your heart, as compared to the most accurate test of right heart catheterization (RHC, also called "Swan" catheter). Echo is a test that uses ultrasound to get pictures of your heart through an ultrasound probe that is placed on your chest or upper abdomen. RHC is a procedure where a catheter is inserted into your heart through a large vein (in your neck or groin), and the pressures within your heart are measured directly. This study will show us if echo measurements can be used reliability in patients in the future without having to do invasive catheterization. Patients undergoing both echo and RHC, as determined by their doctor, while in the hospital as part of standard medical care will be enrolled in this study. There is no additional testing that will be done as part of this study. 
More information about research and clinical trials


A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction (CAPACITY HFpEF)

This study will evaluate the safety and efficacy of 3 doses of IW-1973 compared with placebo, a drug that looks like the study drug but has none of the active ingredients. During the study participants will be asked to take the drug daily for about 12 weeks, 2 weeks of taking the drug twice-daily followed by 10 weeks of taking the drug once-daily. At the Day 1 Visit, patients will spend about 2 hours going through study required assessments to help determine if they qualify for the study. Once those assessments are finished patients will be randomized, randomly assigned to one of the groups: 10mg study drug, 20mg study drug, 40mg study drug, or placebo daily. After Visit 1 participants will be asked to return to the clinical at Week 4, Week 8, and End of Treatment for study drug administration; safety efficacy, and a few additional assessments; and to receive additional study drug and other supplies, as applicable. Patients will return to the clinic 28 days (day 113+/-7) after their last study drug dose for the final Follow-up Visit. 
More information about research and clinical trials


Characterizing HIV-related Diastolic Dysfunction

This is a multicenter clinical trial of a cross section of HIV+ patients with and without diastolic dysfunction. Approximately 200 HAART-treated virally suppressed HIV+ subjects (100 HIV+/DD+ & 100 HIV+/DD-) will be enrolled. Currently only accepted patients who have HIV and Diastolic Dysfunction. This study will evaluate biomarkers, phenomapping, metabolomics, cMRI, and echocardiography to determined characteristics unique to this patient population.
More information about research and clinical trials

Tufts Medical Center and Floating Hospital for Children have high quality care.

Quality + Safety

A world-class teaching hospital shouldn't make you feel small. At Tufts Medical Center the patient is at the center of everything that we do. This means we're committed to providing the highest quality of care in a safe, friendly environment.

Learn about our quality and safety initiatives
The City of Boston shows the harbor and buildings

200 Years of Caring for the Community

Tufts Medical Center has been taking care of Boston and the surrounding community for more than 200 years.

Read about our enduring history